Just as the dust was settling from the Womens Health Initiative (WHI), the FDA Reproductive Health Drugs Advisory Committee's delivered its unanimous vote that safety data are inadequate to support approval of Procter & Gamble's (P&G) testosterone patch (Intrinsa). The patch was developed to treat hypoactive sexual desire disorder (HSDD) in surgically postmenopausal women.
The most universal question is how much data are sufficient to show that a new drug is 'safe enough' to receive initial approval? That is, how many more subjects need to be treated with Intrinsa and what is the minimum number of months or years that subjects must be monitored before the FDA will consider Intrinsa safe for initial approval? The controversial aspect of this very laudable safety concern is whether P&G will need to provide more safety data than is the standard for new medications. If so, is this because of the timing of the request for approval (just after the FDA came under public scrutiny regarding new drug approvals in general and the withdrawal of Vioxx by Merck in particular)? Or, is the push for significantly more safety data a direct reaction to the WHI and the increased fear that hormones are particularly risky for women? Committee member, Steven Nissen, MD, indicated that there are 'four or five pieces of data to suggest that there is a high probability of an excess of cardiovascular risk with this product.' He further stated that in order to conduct a sufficiently powered randomized controlled study, P&G would need at least 5000-10 000 additional subjects. Other committee members suggested conducting studies in high-risk populations, others suggested conducting animal studies to track certain cardiovascular risk markers, and still others suggested studies in premenopausal women since off-label use is likely. While I doubt anyone disagrees with the idea of improved safety, will any risk be acceptable (eg, even Acetaminophen carries a risk of death) for a treatment directed at improving female sexuality? Additionally, although the concern for misuse in high-risk populations is certainly appropriate, the question is how many of these kind of special population studies need to be completed prior to a company requesting initial approval for a treatment. Further, the use of the WHI as an example of the cardiovascular dangers of hormones in postmenopausal women is not necessarily accurate. Even the NIH-funded WHI has been criticized as potentially underpowered to accurately detect cardiovascular events (eg, cardioprotective effects of HT in the menopausal transition) and despite the increased relative risks for cardiovascular disease and breast cancer, estrogens and progestins remain approved by the FDA.
It does not appear that this fear of hormones has generalized to men since testosterone replacement patches and gels for men have been approved without requirements for extensive safety data. In addition, three phosphodiesterase type 5 (PDE5) inhibitors were approved for erectile dysfunction despite concerns about increased risk of myocardial infarction, particularly in high-risk populations, and the well-known recreational use of these medications in men without erectile dysfunction. It occurs to me that this apparent double standard may reflect differing values placed on the importance of sexual health in women versus men.
Before the hearing itself, I believed the medical community was ready to accept and embrace the importance of women's sexuality. It had been a long struggle dating back to the end of the 18th century when female sexuality was considered an oxymoron, and through the Victorian era during which sexual enjoyment by women was considered inappropriate and grounds for institutionalization. In addition to my disappointment about the progress of Intrinsa in the regulatory process, I was even more distressed by the surprisingly negative reactions of many feminists who claim that HSDD was created by the pharmaceutical industry in order for there to be a disease state to treat. As a clinical psychologist who has treated countless women distressed by their loss of sexual desire, I knew this to be untrue. A related argument is that HSDD is so poorly understood as to belie treatment. However complicated women's sexual desire is, decades of research has given us some understanding of the components of desire. How else could treating sexual problems with psychotherapy work effectively? I am baffled by the vehement opposition to finally having a pharmacologic treatment option to what we can offer women. In no way should the reality that a portion of postmenopausal women suffer from a distressing loss of biologic drive dismiss the overall complexity of desire or the reality that it is the context of a woman's life and relationship that is the most important component. It is certainly a valid concern that testosterone replacement, which can help restore only one component of desire-the drive component (the biological component that is experienced as spontaneous sexual thoughts, dreams, erotic daydreams or genital stirring), will be misused. However, this argument, if broadly applied, would apply to dozens of approved drugs (eg tranquilizers, PDE5 Inhibitors, steroids). The potential for misuse does not appear to be a valid reason to prohibit its availability. Nor is the concern that physicians may use it incorrectly.
Besides the acknowledged complexity of female sexuality and desire, one of the major stumbling blocks in prior decades of research was finding valid end points to measure. With male sexual research, end points for dysfunctions such as erectile dysfunction or premature ejaculation are relatively easy to assess. Desire, for men and women, is less concrete an end point. So, as an investigator in the Phase III Intrinsa trials, I was pleased with how P&G attempted to address this by (a) the use of observable behaviors (satisfying sexual events) for their primary end point, while still including the important subjective rating of 'satisfying'; (b) not requiring that 'activity' be defined as intercourse and (c) the use of relevant secondary end points, which were the scores from two validated scales that measure desire and distress. Yet, to my own personal distress, the virtually mandated primary end point was criticized and dismissed by some committee members as not a meaningful benefit. Experts in sexology would point to the fact that desire should not be measured primarily by sexual activity and sex therapists would strongly disagree with the belief that an increase in two satisfying sexual events per month is insignificant to the quality of life for a woman and her partner.
Although HSDD is not life-threatening, it is lifealtering and is prevalent. The World Health Organization has declared that sexual health is a basic human right and the management of sexual health is the responsibility of healthcare providers, particularly those specializing in reproductive health. It is a shame that physicians will have to wait considerably longer before having the ability to offer Intrinsa or any pharmacologic treatment for the most prevalent of female sexual dysfunctions.
